Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®

Core Insights - Mount Sinai Hospital has successfully treated its first prostate cancer patient using the TULSA-PRO system, marking a significant advancement in prostate care with AI-powered, MRI-guided therapy [1][4] Group 1: TULSA Procedure Overview - The TULSA Procedure™ utilizes robotically controlled directional ultrasound to heat prostate tissue to 'kill temperature' (55-57°C), while protecting surrounding nerves, resulting in no procedural blood loss and a quicker recovery [2][9] - This procedure is designed to treat a range of prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH), with minimal side effects such as urinary incontinence and erectile dysfunction [2][8] Group 2: Collaboration and Leadership - Mount Sinai is the first health system in the New York Metro Area to offer the TULSA Procedure, establishing itself as a leader in robotic surgical care [4] - The collaboration between the Department of Urology and the Department of Interventional Radiology at Mount Sinai aims to pave the way for future studies and guidelines in prostate cancer and BPH treatment using TULSA-PRO [5] Group 3: Technology and Market Potential - TULSA-PRO combines real-time MRI, AI-enhanced planning, and temperature feedback control, positioning it as a potential mainstream treatment for various prostate conditions [8] - The procedure is CE marked, Health Canada approved, and 510(k) cleared by the U.S. FDA, indicating its regulatory compliance and market readiness [9]